Literature DB >> 21953030

Analysis of acute-phase proteins, AHSG, C3, CLI, HP and SAA, reveals distinctive expression patterns associated with breast, colorectal and lung cancer.

Paul Dowling1, Colin Clarke, Kim Hennessy, Beatriz Torralbo-Lopez, Jo Ballot, John Crown, Ingrid Kiernan, Kenneth J O'Byrne, M John Kennedy, Vincent Lynch, Martin Clynes.   

Abstract

Early detection, clinical management and disease recurrence monitoring are critical areas in cancer treatment in which specific biomarker panels are likely to be very important in each of these key areas. We have previously demonstrated that levels of alpha-2-heremans-schmid-glycoprotein (AHSG), complement component C3 (C3), clusterin (CLI), haptoglobin (HP) and serum amyloid A (SAA) are significantly altered in serum from patients with squamous cell carcinoma of the lung. Here, we report the abundance levels for these proteins in serum samples from patients with advanced breast cancer, colorectal cancer (CRC) and lung cancer compared to healthy controls (age and gender matched) using commercially available enzyme-linked immunosorbent assay kits. Logistic regression (LR) models were fitted to the resulting data, and the classification ability of the proteins was evaluated using receiver-operating characteristic curve and leave-one-out cross-validation (LOOCV). The most accurate individual candidate biomarkers were C3 for breast cancer [area under the curve (AUC) = 0.89, LOOCV = 73%], CLI for CRC (AUC = 0.98, LOOCV = 90%), HP for small cell lung carcinoma (AUC = 0.97, LOOCV = 88%), C3 for lung adenocarcinoma (AUC = 0.94, LOOCV = 89%) and HP for squamous cell carcinoma of the lung (AUC = 0.94, LOOCV = 87%). The best dual combination of biomarkers using LR analysis were found to be AHSG + C3 (AUC = 0.91, LOOCV = 83%) for breast cancer, CLI + HP (AUC = 0.98, LOOCV = 92%) for CRC, C3 + SAA (AUC = 0.97, LOOCV = 91%) for small cell lung carcinoma and HP + SAA for both adenocarcinoma (AUC = 0.98, LOOCV = 96%) and squamous cell carcinoma of the lung (AUC = 0.98, LOOCV = 84%). The high AUC values reported here indicated that these candidate biomarkers have the potential to discriminate accurately between control and cancer groups both individually and in combination with other proteins.
Copyright © 2011 UICC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21953030     DOI: 10.1002/ijc.26462

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  29 in total

1.  Cancer Secretome May Influence BSP and DSP Expression in Human Salivary Gland Cells.

Authors:  Samantha Lynn Hamilton; Blake Ferando; Asha Sarah Eapen; Jennifer Chian Yu; Anita Rose Joy
Journal:  J Histochem Cytochem       Date:  2016-11-25       Impact factor: 2.479

2.  Single nucleotide polymorphisms of the haptoglobin gene in non-small cell lung cancer treated with personalized peptide vaccination.

Authors:  Kayoko Waki; Teppei Yamada; Koichi Yoshiyama; Yasuhiro Terazaki; Shinjiro Sakamoto; Shunichi Sugawara; Shinzo Takamori; Kyogo Itoh; Akira Yamada
Journal:  Oncol Lett       Date:  2016-12-07       Impact factor: 2.967

3.  Discovery and horizontal follow-up of an autoantibody signature in human prostate cancer.

Authors:  Paul J Mintz; Anna Cecilia Rietz; Marina Cardó-Vila; Michael G Ozawa; Eleonora Dondossola; Kim-Anh Do; Jeri Kim; Patricia Troncoso; Christopher J Logothetis; Richard L Sidman; Renata Pasqualini; Wadih Arap
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-09       Impact factor: 11.205

Review 4.  COPD and squamous cell lung cancer: aberrant inflammation and immunity is the common link.

Authors:  Steven Bozinovski; Ross Vlahos; Desiree Anthony; Jonathan McQualter; Gary Anderson; Louis Irving; Daniel Steinfort
Journal:  Br J Pharmacol       Date:  2015-07-08       Impact factor: 8.739

5.  N-glycoprotein SRMAtlas: a resource of mass spectrometric assays for N-glycosites enabling consistent and multiplexed protein quantification for clinical applications.

Authors:  Ruth Hüttenhain; Silvia Surinova; Reto Ossola; Zhi Sun; David Campbell; Ferdinando Cerciello; Ralph Schiess; Damaris Bausch-Fluck; George Rosenberger; Jingchung Chen; Oliver Rinner; Ulrike Kusebauch; Marián Hajdúch; Robert L Moritz; Bernd Wollscheid; Ruedi Aebersold
Journal:  Mol Cell Proteomics       Date:  2013-02-13       Impact factor: 5.911

6.  Gastric perforation caused by secondary systemic amyloidosis.

Authors:  Hiroto Yamamoto; Akihiko Yokota; Noriyuki Suzuki; Mitsuhiro Tachibana; Yutaka Tsutsumi
Journal:  Clin Case Rep       Date:  2021-05-24

7.  Rapid Noninvasive Skin Monitoring by Surface Mass Recording and Data Learning.

Authors:  Yingdi Zhu; Andreas Lesch; Xiaoyun Li; Tzu-En Lin; Natalia Gasilova; Milica Jović; Horst Matthias Pick; Ping-Chih Ho; Hubert H Girault
Journal:  JACS Au       Date:  2021-03-22

8.  A penalized robust method for identifying gene-environment interactions.

Authors:  Xingjie Shi; Jin Liu; Jian Huang; Yong Zhou; Yang Xie; Shuangge Ma
Journal:  Genet Epidemiol       Date:  2014-02-24       Impact factor: 2.344

9.  Identification of genes involved in breast cancer and breast cancer stem cells.

Authors:  Panagiotis Apostolou; Maria Toloudi; Ioannis Papasotiriou
Journal:  Breast Cancer (Dove Med Press)       Date:  2015-07-15

10.  VeriStrat(®) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib.

Authors:  J L Kuiper; J S W Lind; H J M Groen; J Roder; J Grigorieva; H Roder; A M C Dingemans; E F Smit
Journal:  Br J Cancer       Date:  2012-10-18       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.